Patent Grant Rate

Goal of the analysis:

Measure the proportion of patent applications that mature to grant, understand how grant performance varies by jurisdiction, technology, and counsel, and pinpoint actions that increase allowance probability and speed. For executives, Patent Grant Rate is a quality and ROI signal for the IP pipeline: it links invention efforts and filing spend to enforceable rights. This analysis separates true performance from mix and cohort timing effects, highlights where prosecution strategies stall, and guides resource allocation (outside counsel, examiner engagement, jurisdictions) to improve portfolio value and cost-effectiveness.

Data required:

• Application and family master:
  • Application ID, family ID, priority date, filing date, application type (utility, design, PCT, continuation/divisional/CIP), jurisdiction/office.
  • Status (pending, allowed, granted, abandoned, withdrawn), grant date, publication date.
  • Technology classification (IPC/CPC), internal technology domain, BU/Product mapping.
• Prosecution events and outcomes:
  • Office actions (non-final/final), examiner interviews, RCEs/divisionals, amendments, IDS submissions.
  • Appeals, oppositions (EPO), observations, withdrawals, continuation filings.
  • Examiner/art unit (USPTO) or technical field (EPO/JPO/CNIPA), first action pendency, prosecution history metadata.
• Portfolio context and quality indicators:
  • Claim counts, independent claims, earliest priority chain details.
  • Linkage to invention disclosures, prior art search results, and internal quality scores (if used).
  • Outside counsel firm/attorney, internal owner, prosecution budget and spend (for efficiency overlays).
• External references (optional but valuable):
  • Public databases (USPTO, EPO, WIPO) for examiner/art unit statistics and allowance benchmarks.
  • Competitor application status for relative grant performance by domain.
• Systems and mapping:
  • IPMS/docketing (e.g., Anaqua, CPA Global/Clarivate, FoundationIP), disclosure portals, cost systems.
  • Taxonomy mappings (CPC/IPC → internal domains), BU/region/product masters.

Detailed step-by-step instruction on how to conduct the analysis:

1. Define metrics and cohort rules.
   • Application-level Grant Rate (cohort) = Granted ÷ Disposed (Granted + Abandoned/Withdrawn). Exclude Pending to avoid censoring bias.
   • Family-level Grant Rate = Families with ≥1 granted application ÷ Families disposed.
   • Jurisdiction Grant Rate = Granted ÷ Disposed within each office (USPTO, EPO, CNIPA, JPO, etc.).
   • Time-to-Grant (median, 75th/90th percentiles) by office/domain for speed diagnostics.
   • Define cohorts by filing year (or priority year) to control for prosecution lifecycle length.
2. Extract and unify data.
   • Pull application and family tables from IPMS with statuses and dates; include prosecution events, examiner/art unit, and counsel data.
   • Normalize application types and statuses across jurisdictions; ensure unique family IDs and correct priority chains.
   • Join to BU/product and technology domain mappings; include spend (optional) for efficiency overlays.
3. Cleanse and validate.
   • Remove duplicates (system migrations), fix impossible sequences (grant before filing), and reconcile continuations/divisionals to parent families.
   • Check jurisdiction consistency (e.g., national phase entries tied to PCT numbers) and grant/abandon dates.
   • Confirm pending count by cohort so disposed denominator is sound.
4. Compute core KPIs.
   • For each filing-year cohort and jurisdiction:
     • Disposed count, Granted count, Abandoned count, Grant Rate = Granted/Disposed.
     • Median Time-to-Grant (from filing to grant).
     • Office Action Count to Allowance (mean/median), RCE Rate (USPTO), Appeal Rate and success.
     • Continuation/Divisional Share among grants (signals strategy/mix).
   • Portfolio-wide:
     • Application- vs Family-level Grant Rates.
     • Domain- and BU-level rates.
     • Grant Rate normalized by examiner/art unit difficulty (benchmark-adjusted index).
5. Segment and compare performance.
   • By jurisdiction, technology domain (CPC/IPC), BU/product line, outside counsel firm/attorney, examiner/art unit.
   • By application type (original vs continuation/divisional; PCT national entries vs direct filings).
   • By claim set size and internal quality scores (if available).
6. Trend and cohort analysis.
   • Track Grant Rate over time by filing cohort (e.g., 2018–2022) to avoid pending bias; show partial cohorts (recent years) separately.
   • Plot Time-to-Grant medians by cohort and office; monitor pendency improvements/deterioration.
7. Driver diagnostics.
   • Examine correlations: higher office action counts and RCE rates typically depress grant rate or extend time; examiner interviews can lift allowance.
   • Identify outlier examiners/art units and compare counsel strategies and interview usage.
   • Assess effect of continuations/divisionals: may inflate grant counts without net new scope; inspect claim strategy.
   • Overlay spend: compute cost-to-grant by counsel/jurisdiction for efficiency.
8. Quality checks.
   • Ensure abandoned cases include explicit abandon/withdraw codes; separate formal abandonment from docketing errors.
   • Validate grant events via public databases for top matters; confirm continuity data.
   • Guard against survivorship bias by reporting pending share alongside grant metrics.
9. Set targets and alerts.
   • Targets by jurisdiction/domain (e.g., USPTO application-level grant rate ≥60–75% depending on art unit mix; EPO ≥50–70%).
   • Operational thresholds: median Time-to-Grant targets; maximum office actions before strategy escalation; interview utilization ≥X% in tough art units.
   • Alerts for cohorts or domains deviating negatively from benchmarks or internal top quartile.
10. Institutionalize governance.
    • Quarterly IP committee reviews: grant and pendency KPIs, examiner/counsel scorecards, action plans for outliers.
    • Feedback loop to invention triage and claim drafting standards based on prosecution learnings.

Format of the output of analysis:

• Executive KPI summary: application- and family-level Grant Rates by jurisdiction, median Time-to-Grant, office action and RCE rates, benchmark-adjusted index.
• Cohort charts by filing year: Disposed vs Pending, Grant Rate, Time-to-Grant medians.
• Heatmaps by technology domain, BU/product, outside counsel, and examiner/art unit with traffic-light thresholds.
• Prosecution funnel: Filed → First action → Interview → Allowance → Grant, with drop-offs and median days per stage.
• Counsel scorecards: grant rate, time-to-grant, office actions per grant, cost-to-grant.
• Appendix: metric definitions (disposed basis), counting rules (family vs application; PCT/national phase), data sources, and quality checks.

How to interpret results:

• Higher Grant Rate with stable or improving Time-to-Grant indicates effective claims and prosecution strategy; if Time-to-Grant increases, review negotiation tactics and examiner mix.
• Low Grant Rate in specific domains often reflects difficult art units or weak prior art positions; compare to benchmark-adjusted indices to separate skill from mix.
• High continuation/divisional share with good grant rates may mask limited new scope; ensure filings align with commercial coverage needs.
• Large gaps between application- and family-level rates suggest families rely on a single jurisdiction; revisit coverage strategy for key markets.
• High RCE and appeal rates inflate time and cost; increased examiner interviews and targeted amendments can reduce cycles.
• Recent cohorts will show lower apparent grant rates due to pendency; rely on older cohorts for definitive performance and use survival/pendency curves to forecast.

Steps a company can take to improve on this measure:

• Prosecution strategy and quality:
  • Strengthen pre-filing prior art searches and claim drafting standards; require internal quality checklists and claim charts tied to product features.
  • Adopt examiner interview-first protocols after first action; use pilot programs (e.g., AFCP 2.0 at USPTO) and accelerated routes where ROI justifies.
  • Escalate to pre-appeal brief review when office action cycles exceed thresholds; apply targeted continuations for strategic scope, not as default.
• Outside counsel and examiner management:
  • Allocate work by domain to firms with demonstrably higher benchmark-adjusted grant rates and faster pendency.
  • Coach counsel on examiner-specific strategies; track interview rates, amendment practices, and outcome lift by firm.
• Portfolio and jurisdiction choices:
  • Align jurisdiction coverage to revenue/manufacturing/competitor regions; avoid low-value filings with chronic low grant likelihood.
  • Use PCT to manage uncertainty; set disciplined national phase go/no-go gates at 18–24 months using search/opinion quality and commercial traction.
• Data, systems, and analytics:
  • Enrich IPMS with examiner/art unit benchmarks and counsel performance data; automate cohort Grant Rate and pendency dashboards.
  • Implement survival analysis to forecast grants for recent cohorts; add cost-to-grant metrics for ROI.
• Capability and governance:
  • Train engineers and patent drafters on claim strategy and prosecution tactics; run post-grant retrospectives to capture lessons.
  • Institute quarterly IP committee with BU leaders to review grant performance vs targets and adjust filing strategy.
• Scenario guidance:
  • If USPTO grant rate lags benchmarks in a few art units: switch to specialist counsel, increase interviews, and refine claim sets; consider Track One acceleration for high-value cases.
  • If EPO grants are slow: improve response quality to search opinions, consider divisional timing strategy, and leverage examiner consultation meetings.
  • If continuations drive grants but new families lag: revisit invention harvesting and quality gates; prioritize first-filings aligned to roadmap.

Benchmark comparisons:

General benchmarks:

• Application-level Grant Rates (indicative; vary by art unit/office and mix):
  • USPTO: ~55–75% overall; top-performing portfolios (benchmark-adjusted) reach 70%+.
  • EPO: ~50–70% (stricter unity and added scrutiny vs USPTO).
  • JPO/KIPO: often 60–80% with relatively faster pendency for well-prepared cases.
  • CNIPA: ~45–70% depending on domain and translation/claim practice quality.
• Time-to-Grant (median):
  • USPTO: 24–36 months; accelerated (Track One) ~12–18 months.
  • EPO: 30–48 months; can be longer in complex fields.
  • JPO/KIPO: 18–30 months; CNIPA: 20–36 months.
• Prosecution intensity:
  • Office actions to allowance (USPTO): 1.5–3.0 typical; RCE rates 20–40% depending on domain.

Segment- or industry-specific benchmarks:

• Software/computer-implemented inventions: wider variance at USPTO/EPO; grant rates lower in certain art units—interview strategy and claim drafting are critical.
• Electronics/telecom: moderate-to-high grant rates with heavy continuation practice in the US.
• Medtech/devices: strong grant rates with rigorous prior art; EPO timelines can be longer.
• Chemistry/materials: generally solid grant rates; EPO unity and inventive step can drive divisional strategies.

If external benchmarks are not fully comparable, construct internal ones: use 5-year filing cohorts by jurisdiction and domain; compute grant rates on a disposed basis; create benchmark-adjusted indices using examiner/art unit mix; set targets using internal top quartile by domain and counsel; and review annually to reflect mix shifts and policy changes at patent offices.